NEWYou can now listen to Fox News articles!

An oral weight loss pill has performed well in clinical trials, positioning it as a potential alternative to injectable GLP-1 medications like Ozempic and Wegovy.

The Eli Lilly drug, called orforglipron, demonstrated “meaningful weight loss” and cardiometabolic improvements, according to a press release.

The phase 3 ATTAIN-1 trial, which was published in the New England Journal of Medicine, evaluated the safety and efficacy of the drug in adults who have a weight-related medical problem and do not have diabetes.

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT

The participants underwent 72 weeks of treatment with three different doses (6 mg, 12 mg and 36 mg).

After the trial period, results showed that orforglipron

See Full Page